Clarity Pharmaceuticals (Clarity Pharmaceuticals) Net Income From Continuing Operations : $-20.48 Mil (TTM As of Dec. 2023)

View and export this data going back to 2022. Start your Free Trial

What is Clarity Pharmaceuticals Net Income From Continuing Operations?

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Clarity Pharmaceuticals's net income from continuing operations for the six months ended in Dec. 2023 was $-11.52 Mil. Its net income from continuing operations for the trailing twelve months (TTM) ended in Dec. 2023 was $-20.48 Mil.

Clarity Pharmaceuticals Net Income From Continuing Operations Historical Data

The historical data trend for Clarity Pharmaceuticals's Net Income From Continuing Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Clarity Pharmaceuticals Net Income From Continuing Operations Chart

Clarity Pharmaceuticals Annual Data

Trend

Jun22

Jun23

Net Income From Continuing Operations

-16.69

-16.51

Clarity Pharmaceuticals Semi-Annual Data
	Dec20	Dec21	Jun22	Dec22	Jun23	Dec23
Net Income From Continuing Operations	Get a 7-Day Free Trial			-9.81	-7.06	-7.59	-8.97	-11.52

Clarity Pharmaceuticals Net Income From Continuing Operations Calculation

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Net Income From Continuing Operations for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was $-20.48 Mil.

Clarity Pharmaceuticals (Clarity Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Clarity Pharmaceuticals Ltd (OTCPK:CLRPF) » Definitions » Net Income From Continuing Operations

Comparable Companies

Traded in Other Exchanges

CU6:Australia

Address

4 Cornwallis Street, National Innovation Centre, Eveleigh, Sydney, NSW, AUS, 2015

Website

https://www.claritypharmaceuticals.com

Clarity Pharmaceuticals Ltd is a clinical-stage radiopharmaceutical company developing next-generation theranostic (therapy and imaging) products, based on its platform SAR Technology. The SAR technology is ideally suited for use with copper isotopes, enabling superior imaging and therapeutic characteristics of radiopharmaceutical products and addressing the current manufacturing and logistical limitations in the growth of the radiopharmaceutical sector in oncology.